3 Bryant Park at 1095 Avenue of the Americas
28th Floor
New York, NY 10036
The event will include an update on the status of Zealand's business and its progress towards becoming a leader in specialty gastrointestinal and metabolic diseases. Management will present the progress and outlook for glepaglutide and dasiglucagon as well as an update on the strong research pipeline.